[Effect of 153Sm-EDTMP on hematopoiesis and vital organs of 93 patients with bone tumor].
In the present study data on blood cell count, serum biochemistry, electrolyte, enzyme and vital organs of 93 patients with bone tumor or metastasis were investigated before and after treatment with 153Sm-EDTMP. The results showed that, 7 days and 30 days after the administration of 153Sm-EDTMP (< 29.6 MBq) (0.8 mCi/kg), the levels of hemoglobin, WBC lymphocyte count, and the liver and kidney function of all patients were not significantly different from the baseline data before treatment (P > 0.05). Although at 7 days, there was a declination of the granulocyte count, it returned to normal at 30 days (P > 0.05). The platelet count was significantly decreased (0.05 > P > 0.01). at 30 days after the administration of 153Sm-EDTMP. Thirteen patients received 74-185 MBq (2-5mCi/kg) and their myelo biopsies at 3 and 18 months showed no sign of acute or chronic toxicosis.
D000328:Adult; D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology; D005260:Female; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000473:pathology; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D010976:Platelet Count / Q000187:drug effects; D011868:Radioisotopes / Q000627:therapeutic use*; D012493:Samarium / Q000627:therapeutic use*
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam